{"title":"[Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster].","authors":"Sachi Morita, Noritoshi Kobayashi, Junji Tsurutani, Haruko Daga, Emiko Ohki, Takami Kashiwada, Kentaro Kawakami, Yoshiko Kitagawa, Masaki Maruta, Yasuhiro Fujiwara, Hironobu Minami","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the\"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection\". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 8","pages":"573-576"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
